Methodology and potential pitfalls in allergic diseases study designs: Measurements for the assessment of the overall severity of atopic dermatitis - The four step severity score' (FSSS), SCORAD-related, electronic system, for the simple and rapid evaluation of the skin and mucosal allergic inflammation

European Annals of Allergy and Clinical Immunology

Volumn 37, Issue 9, 2005, Pages 357-361

  Mastrandrea, F ^a   Pecora, S ^b   Scatena, C ^b   Cadario, G ^c  

^a SS Annunziata Hospital   (Italy)

^b Medical Service   (Italy)

^c A O Molinette   (Italy)

Author keywords

Assessment; Atopic dermatitis, allergic disease, allergic inflammation; Classification, four step severity score; FSSS; Severity; Specific immunotherapy; Study design

Indexed keywords

PLACEBO;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ATOPIC DERMATITIS; COMPUTER ASSISTED DIAGNOSIS; COMPUTER PROGRAM; DISEASE COURSE; DISEASE SEVERITY; ELECTRONICS; EVALUATION; EVIDENCE BASED MEDICINE; HAY FEVER; HEALTH STATISTICS; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MEASUREMENT; MEDICAL DECISION MAKING; METHODOLOGY; MUCOSA INFLAMMATION; OUTCOMES RESEARCH; PATHOGENESIS; QUALITY CONTROL; REVIEW; SCORING SYSTEM; SKIN ALLERGY;

ASTHMA; CLINICAL TRIALS; DERMATITIS, ATOPIC; HUMANS; RESEARCH DESIGN; RHINITIS; SOFTWARE;

EID: 28944450580     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Johansson SG, Bieber T. - New diagnostic classification of allergic skin disorders. Curr Opin Allergy Clin Immunol 2002;2:403-6.
2. Uchida T, Suto H, Ra C, Ogawa H, Kobata T, Okumura K. - Preferential expression of T(h) 2-type chemokine and its receptor in atopic dermatitis. In: Immunol 2002;14:1431-8.
3. La Grutta S, Richiusa P, Pizzolanti G et al. - CD4IL-13 cells in peripheral blood well correlates with the severity of atopic dermatitis in children. Allergy 2005;60:391-5.
4. Dieckoff K, Graf P, Beinhauer B et al. - Deficient translocation of c-Rel is associated with impaired Th1 cytokine production in T cells from atopic dermatitis patients. Exp Dermatol 2005;14:17-25.
5. Chen L, Martinez O, Overberg L et al. - Early up-regulation of Th2 cytokines and late surge of TH1 cytokines in atopic dermatitis model. Clin Exp Immunol 2004;138:375-87.
6. Antunez C, Torres MJ, Corzo JL et al. - Different lymphocyte markers and cytokine expression in peripheral blood mononuclear cells in children with acute atopic dermatitis. Allergol Immunophatol 2004;32:252-8.
7. Vestegaard C, Deleuran M, Gessere B et al. - Expression of the T-helper 2-specific chemokine receptor CCR4 on CCR10-positive lymphocytes in atopic dermatitis skin but not in psoriasis skin. Br J Dermatol 2003;149:457-63.
8. Jacob SE, Nassiri M, Kerdel FA, Vincek V. - Simultaneous measurement of multiple Th1 and TH2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 2003;12:309-13.
9. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. - Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004;135:1-8.
10. Ramirez F. - Glucocorticoids induce a Th2 response in vitro. Dev Immunol 1998;6:233-43.
11. Williams CM, Colemann JW. - Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A. Immunology 1995;86:244-9.
12. Wu CY, Wang K, Mc Dyer JF, Seder RA. - Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol 1998;161:2723-30.
13. Visser J, van Boxel-Dezaire A, Methorst D et al. - Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro. Blood 1998;91:4255-64.
14. Jabara HH, Ahern DJ, Vercelli D, Geha RS. - Hydrocortisone and IL-4 induce IgE isotype switching in human B cells. J Immunol 1991;147:1557-60.
15. Zieg G, Lack G, Harbeck RJ et al. - In vivo effects of glucocorticoids on IgE production. J Allergy Clin Immunol 1994;94:222-30.
16. Akdis CA, Blesken T, Akdis M et al. - Glucocorticoids inhibit human antigen-specific and enhance total IgE and IgG4 production due to differential effects on T and B cells in vitro. Eur J Immunol 1997;27:2351-7.
17. Jabara HH, Brodeur SR, Geha RS. - Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching. J Clin Invest 2001;107:371-8.
18. Barnes PJ. - Corticosteroids, IgE, and atopy. J Clin Invest 2001;107:265-6.
19. Chen SS, Stanescu G, Magalski AE, Qian YY. - Cyclosporin A is an adjuvant in murine IgE antibody responses. J Immunol 1989;142:4225-32.
20. Weeler DJ, Robins A, Pritchard DI et al. - Potentiation of in vitro synthesis of human IgE by cyclosporin A (CsA). Clin Exp Immunol 1995;102:85-90.
21. Nagai H, Hiyama H, Matsuo A et al. - FK-506 and cyclosporin A potentiate the IgE antibody production by contact sensitization with hapten in mice. J Pharmacol Exp Ther 1997;283:321-7.
22. Kawamura N, Furuta H, Tame A et al. - Extremely high serum level of IgE during immunosuppressive therapy: paradoxical effect of cyclosporin A and tacrolimus. Int Arch Allergy Immunol 1997;112:422-4.
23. Mastrandrea F, Minardi A, Coradduzza G, Rossi N, Cadario G. - Atopic Dermatitis: towards a plausible pathogenetic model. Ital J Allergy Clin Immunol 1998;8:503-17.
24. Mastrandrea F, Cadario G, Bedello PG, Nicotra MR, Natali PG. - Expression of T-lineage early developmental markers by cells establishing atopic dermatitis skin infiltrates. Invest Allergol Clin Immunol 1998;8:359-364.
25. Mastrandrea F, Cadario G, Nicotra MR, Natali PG. - Hemopoietic progenitor cells in atopic dermatitis skin lesions. Invest Allergol Clin Immunol 1999;9:386-91.
26. Mastrandrea F. - The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. Leading article. Am J Clin Dermatol 2004;5:281-294.
27. Cameron L, Christodoulopoulos P, Lavigne F et al. - Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor. J Immunol 2000;164:1538-45.
28. Stirling RG, van Resen EL, Barnes PJ, Chung KF. - Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Resp Crit Care Med 2001;164:1403-9.
29. Mwamtemi HH, Koike K, Kinoshita T, Ito S, Ishida S, Nakazawa Y et al. - An increase in circulating mast cell colony-forming cells in asthma. J Immunol 2001;166:4672-7.
30. Kim YK, Uno M, Hamilos DL, Beck L, Bochner B, Schleimer R, Denburg JA. - Immunolocalization of CD34 in nasal polyposis. Am J Respir Cell Mol Biol 1999;20:388-97.
31. Cyr MM, Denburg JA. - Systemic aspect of allergic disease: the role of the bone marrow. Curr Opin Immunol 2001;13:727-32.
32. Mastrandrea F. - Natural history and pathogenesis of allergic disease. Proc. of the II AAITO National Congress, 15-18 Dec. 2004, Ancona, Italy.
33. Cantani A. - The growing genetic links and the early onset of atopic diseases in children stress the unique role of the atopic march: a meta-analysis. J Invest Allergol Clin Immunol 1999;9:314-20.
34. Gustafsson D, Sjoberg O, Foucard T. - Development of allergies and asthma in infants and young children with atopic dermatitis -a prospective follow-up to 7 years of age. Allergy 2000;55:240-5.
35. Ohshima Y, Yamada A, Hiraoka M et al. - Early sensitisation to house dust mite is a major risk factor for subsequent development of bronchial asthma in Japanese infants with atopic dermatitis: results of 4-year followup study. Ann Allergy Asthma Immunol 2002;89:265-70.
36. Eichenfield LF, Hanifin JM, Beck LA et al. - Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 2003;111:608-16 Marquis D. How to resolve an ethical dilemma concerning randomized clinical trials. N Engl J Med 1999;341:691-93.
37. Benson K, Hartz AJ. - A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;242:1878-86.
38. Concato J, Shah N, Horwitz RI. - Randomized, controlled trials, observational studies and the hierarchy of research design. N Engl J Med 2000:342:1887-92.
39. Hrobjartsson A, Gotzsche PC. - Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-602.
40. JC Bailar III. Editorial. - The powerful placebo and the Wizard of Oz. New Engl J Med 2001;344:1630-32.
41. Pucci N, Lombardi E, Novembre E et al. - Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity. J Allergy Clin Immunol 2000;105:353-7.
42. Stalder JF, Taieb A, Atherton DJ. - Severity scoring of atopic dermatitis: The SCORAD Index. Dermatology 1993;186:23-31.
43. Diepgen TL, Sauerbrei W, Fartasch M. - Development and validation of diagnostic scores for atopic dermatitis incorporating criteria of data quality and pratical usefulness. J Clin Epidemiol 1996;49:1031-8.
44. Charman D, Varigos G, Horne DJ, Oberklaid F. - The development of a pratical and reliable assessment measure for atopic dermatitis (ADAM). J Outcome Meas 1999;3:21-34.
45. Wolkkerstorfer A, de Waard van der Spek FB, Glazenburg EJ, Mulder PG, Oranje AP. - Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily pratice and as a pre-screening tool for studies. Acta Derm Venereol 1999;79:356-9.
46. Hanifin JM, Thurston M, Omoto M et al. - The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11-8.
47. Charman CR, Venn AJ, Williams HC. - Reliability testing of the Six Area, Six Sign Atopic Dermatitis severity score. Br J Dermatol 2002;146:1057-60.
48. Sprikkelman AB, Tupker RA, Burgerhof H et al. - Severity scoring of atopic dermatitis: a comparison of three scoring systems. Allergy 1997;52:944-9.
49. Charman CR, Venn AJ, Williams HC. - Measurement of body surface area involvement in atopic eczema: an impossible task? Br J Dermatol 1999;140:109-11.
50. Charman C, Williams H. - Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000;136:763-9.
51. Liter W, Schwanitz HJ, Pfahlberg A, Gefeller O. - Atopic signs and symptoms: assessing the 'atopy score' concept. Dermatology 2001;202:4-8.
52. Ben-Gashir MA, Hay RJ. - Reliance of erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts. Br J Dermatol 2002;147:920-5.
53. Charman C, Chamber C, Williams H. - Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring? J Invest Dermatol 2003;120:932-41.
54. Allergic rhinitis and its impact on asthma. - ARIA Workshop Report. J Allergy Clin Immunol 2001 Nov; 108 Suppl. 5.
55. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 2000;30Suppl. 1:2-5.
56. Mastrandrea F, Serio G, Minelli M et al. - Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow up of 35 consecutive patients. Allergol Immunopathol 2000;28:54-62.
57. Mastrandrea F. - Immunotherapy in atopic dermatitis. Exp Opin Invest Drugs 2001;10:49-63.
58. Smith GCS, Pell JP. - Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003;327:1459-61.